— Know what they know.
Not Investment Advice

ERGO OTC

Entia Biosciences, Inc.
1W: +25.0% 1M: +25.0% 3M: +400.0% YTD: +233.3% 1Y: +900.0% 3Y: -96.9% 5Y: -85.1%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 61 · $33661 mcap · 20M float · 0.0018% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.0403
Volume150
Avg Volume343
Beta3.27
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOTimothy A. Timmins
Employees6
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2008-01-18
13565 SW Tualatin-Sherwood Road
Sherwood, OR 97140
US
971-228-0709
About Entia Biosciences, Inc.

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
HAUSMAN MARVIN S MD A-Award 250,000 — 2017-02-16
JOHNSON CARL J A-Award 250,000 — 2017-02-16
HAUSMAN MARVIN S MD A-Award 300,000 — 2017-02-14
HAUSMAN MARVIN S MD A-Award 200,000 — 2017-02-14
HAUSMAN MARVIN S MD A-Award 600,000 — 2017-02-14

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms